United States Bioanalytical Testing Services Market By Molecule (Small Molecule, Large Molecule), By Test (ADME, Pharmacokinetics (PK), Pharmacodynamics (PD), Bioavailability, Bioequivalence, Biomarker Testing, Cell-based Assay, Virology Testing, Others), By Workflow (Sample Collection and Preparation, Method Development and Validation, Sample Analysis, Other Processes), By End User (Pharma & BioPharma Companies, CDMO, CRO, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

The United States Bioanalytical Testing Services Market was valued at USD 2.03 Billion in 2024 and is expected to reach USD 3.49 Billion by 2030 with a CAGR of 9.41% through forecast period. The United States bioanalytical testing services market is experiencing robust growth, driven by the increasing number of clinical trials and the expanding pipeline of biologics and biosimilars. The shift from small molecule drugs to complex biologics has created a strong demand for specialized testing services that can support pharmacokinetics, pharmacodynamics, and bioequivalence studies. Pharmaceutical and biotechnology companies are outsourcing these services to reduce development timelines and adhere to regulatory compliance. The need for high-quality analytical data to meet the requirements of the U.S. Food and Drug Administration (FDA) is further propelling market growth. The rise in personalized medicine and the development of targeted therapies are contributing to the need for advanced analytical technologies and tailored testing methodologies.

Technological advancements such as high-resolution mass spectrometry, automated platforms, and data-integrated laboratory information management systems (LIMS) are enhancing the capabilities of bioanalytical laboratories. These tools allow for more accurate, reproducible, and efficient testing of complex drug compounds, especially for large molecules and cell-based therapies. Demand is growing for ligand-binding assays, chromatographic techniques, and biomarker analysis, which are essential in evaluating the safety, efficacy, and pharmacokinetic properties of drug candidates. The expansion of GLP-certified and GCLP-compliant laboratories is also supporting sponsors' need for regulatory submission-ready data. The adoption of advanced data analytics is becoming a key trend, offering real-time monitoring and predictive insights for drug development.

Despite the positive outlook, the market faces challenges related to regulatory complexity, high operational costs, and the shortage of skilled professionals with expertise in bioanalytical methods. The evolving regulatory landscape demands continuous updates in testing protocols, documentation standards, and data integrity measures. Maintaining compliance while investing in state-of-the-art technologies and training programs adds to the financial pressure for service providers. In addition, intense competition among contract research organizations (CROs) may impact pricing strategies and margin sustainability. These challenges need strategic responses to sustain growth and innovation in the United States bioanalytical testing services market.

Key Market Drivers

Rising Demand for Biologics and Biosimilars

The rising demand for biologics and biosimilars is a pivotal driver propelling the growth of the United States bioanalytical testing services market. As the pharmaceutical industry increasingly focuses on complex biological products, the necessity for precise and sensitive bioanalytical methods has become paramount. Biologics, including monoclonal antibodies, vaccines, gene therapies, and cell-based therapies, require specialized testing protocols due to their structural complexity and unique pharmacokinetic profiles. Unlike traditional small-molecule drugs, biologics demand rigorous evaluations, such as ligand-binding assays, immunogenicity testing, and pharmacokinetics/pharmacodynamics (PK/PD) studies. This shift compels pharmaceutical and biotechnology companies to collaborate with bioanalytical service providers that offer advanced scientific expertise and cutting-edge analytical platforms.

Biosimilars, which are highly similar to reference biologics, introduce additional complexity and regulatory scrutiny. These products must undergo extensive comparative analytical testing to establish similarity in terms of safety, efficacy, and immunogenicity. In 2024, the U.S. Food and Drug Administration (FDA) approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition. The FDA has approved 63 biosimilars across 17 unique reference products, with many biosimilar products competing against the same reference product.​

The continued innovation in biologics, encompassing antibody-drug conjugates, fusion proteins, and mRNA-based therapies, reinforces the need for tailored analytical strategies. Bioanalytical testing firms capable of supporting method development, validation, and compliance under Good Laboratory Practice (GLP) conditions are well-positioned to capture market share. The expanding biologics pipeline, coupled with a supportive regulatory environment and increasing adoption of biosimilars in the U.S. healthcare system, accelerates reliance on bioanalytical testing services throughout all phases of drug development.

Growth in Outsourced R&D by Pharma and Biotech Firms

The increasing trend of pharmaceutical and biotechnology companies outsourcing research and development (R&D) activities is a significant driver of the United States bioanalytical testing services market. As drug development becomes more complex and costly, many organizations are turning to specialized contract research organizations (CROs) to streamline operations, reduce overhead expenses, and access advanced scientific expertise. This approach allows sponsors to focus on core competencies while relying on external partners for specialized testing such as pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity studies. The outsourcing model enhances flexibility in project management, shortens development timelines, and enables scalability across different phases of clinical trials.

In 2021, microbusinesses in the United States spent approximately USD 7.3 billion on domestic R&D, with USD 1.1 billion allocated to outsourced R&D services. This indicates that 16% of domestic R&D costs were directed toward external R&D services, highlighting the growing reliance on specialized external partners for conducting complex bioanalytical testing. The trend is particularly pronounced among smaller firms that may lack the resources to establish in-house testing capabilities. By outsourcing, these companies can access cutting-edge technologies, ensure compliance with regulatory standards, and accelerate the development of new therapies.

The increasing demand for biologics, biosimilars, and personalized medicine further fuels the need for specialized bioanalytical testing services. As the complexity of drug candidates rises, the expertise and infrastructure provided by CROs become essential for meeting regulatory requirements and ensuring the safety and efficacy of new treatments. This shift towards outsourcing bioanalytical testing is reshaping the drug development landscape, positioning CROs as critical partners in the successful commercialization of innovative therapies.

Expansion of Clinical Trials and Personalized Medicine

​The expansion of clinical trials and personalized medicine significantly drives the United States bioanalytical testing services market. As pharmaceutical and biotechnology companies increasingly focus on targeted therapies and personalized treatment regimens, the demand for bioanalytical testing services has surged. Personalized medicine involves using genetic, biomarker, and other diagnostic data to tailor treatments to individual patients, necessitating highly specialized testing services. These services are essential for assessing the efficacy and safety of personalized therapies and developing companion diagnostics to identify suitable patients for specific treatments.​

Clinical trials are expanding as new treatments, particularly biologics and biosimilars, enter the market. These treatments require rigorous bioanalytical testing at every phase of clinical trials to ensure their pharmacokinetics, pharmacodynamics, and immunogenicity are well-understood. Given the increasing complexity of clinical trials, there is a growing need for advanced testing methods, including biomarker quantification, immunoassays, and large molecule analysis. The rise in clinical trials for oncology, rare diseases, and genetic disorders further emphasizes the importance of bioanalytical testing to ensure that treatments are both safe and effective for specific patient populations.​

The convergence of the expanding clinical trials and the rise of personalized medicine has led to an increased demand for bioanalytical testing services capable of meeting the precise requirements of these complex therapies. Consequently, testing laboratories are adapting by adopting cutting-edge technologies and expanding their capabilities to include genomics, proteomics, and molecular diagnostics, thereby accelerating the development of innovative medical treatments. This shift is driving significant growth in the bioanalytical testing market in the United States.​

According to data from ClinicalTrials.gov, the number of registered clinical studies in the United States has been steadily increasing, reflecting the growth of clinical trials across various therapeutic areas. This growth necessitates advanced bioanalytical testing services to support the complex requirements of modern clinical research.​

Furthermore, the U.S. government's initiatives to enhance health data interoperability, as outlined by the Office of the National Coordinator for Health Information Technology (ONC), are expected to facilitate the integration of personalized medicine approaches. These efforts aim to improve the exchange and use of electronic health information, supporting the development and implementation of personalized treatments. Such initiatives underscore the importance of bioanalytical testing services in advancing personalized medicine and, consequently, drive market growth.​

Download Free Sample Report

Key Market Challenges

High Operational Costs and Investment Requirements

High operational costs and significant investment requirements represent a substantial challenge for the United States bioanalytical testing services market. Bioanalytical laboratories require state-of-the-art equipment and highly specialized personnel, both of which contribute to elevated operational expenses. Equipment such as mass spectrometers, chromatographs, and other testing instruments are not only expensive to purchase but also require regular maintenance and calibration to ensure accuracy and compliance with regulatory standards. The costs associated with these sophisticated instruments, along with the need for specialized infrastructure to support large-scale testing, create a financial burden for testing providers, particularly small and medium-sized laboratories.

In addition to equipment costs, bioanalytical testing services must comply with stringent regulatory requirements set by agencies such as the FDA and EMA, which often entail costly certification processes, ongoing audits, and validation procedures. The need for adherence to Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) further increases operational overheads. To stay competitive, bioanalytical testing service providers must continually invest in updating their methodologies, technology, and staff training, which further strains financial resources.

This environment is particularly challenging for emerging testing services or those in the early stages of expansion. Without significant capital investment or the ability to scale operations efficiently, these organizations face difficulty in maintaining profitability. The need for heavy investment in new technologies, skilled workforce, and compliance infrastructure can delay market entry for smaller players and limit their growth potential. These high operational costs and substantial upfront investment requirements are expected to hinder the expansion of smaller firms and slow the market’s overall growth in the near term.

Shortage of Skilled Bioanalytical Scientists

The United States Bioanalytical Testing Services Market faces a significant challenge due to the shortage of skilled bioanalytical scientists. The increasing demand for complex bioanalytical testing services driven by the growth of biologics, biosimilars, and personalized medicine has outpaced the availability of highly qualified professionals in this niche field. Bioanalytical testing requires expertise in advanced techniques such as mass spectrometry, liquid chromatography, and bioassays, which demand specialized training and experience. The shortage of trained professionals not only slows down the pace of research and development but also limits the ability of service providers to scale operations efficiently.

The problem is compounded by the rapid advancements in analytical technologies, which require constant upskilling. Bioanalytical scientists must stay abreast of new methodologies and regulatory requirements, which adds to the strain on existing personnel. Educational institutions are struggling to keep pace with the increasing demand for skilled graduates, leading to a talent gap in the market. As a result, companies are facing difficulties in recruiting and retaining top-tier scientists.

This shortage results in increased competition for qualified professionals, driving up salaries and placing additional financial pressures on bioanalytical service providers. For smaller or mid-sized firms, this can be a substantial barrier to entry, as they may lack the resources to compete for top talent. Additionally, the training and development costs for existing employees further strain operational budgets, making it more difficult to deliver high-quality services at competitive prices. This talent shortage, if unresolved, could limit the growth potential of the bioanalytical testing services market in the United States.

Key Market Trends

Growing Focus on Biomarker Development and Companion Diagnostics

​The growing emphasis on biomarker development and companion diagnostics significantly influences the United States bioanalytical testing services market. Biomarkers which are biological indicators of disease presence or progression are pivotal in personalized medicine, enabling tailored treatment strategies. Companion diagnostics are tests that identify patients likely to benefit from specific therapies, ensuring effective and safe treatment regimens.​

In oncology, the FDA has approved numerous companion diagnostic devices to align with targeted therapies. For instance, the FoundationOne Liquid CDx test, approved in 2020, detects tumor mutations in solid tumors, guiding treatment decisions for therapies like Vitrakvi (larotrectinib). This approval exemplifies the FDA's commitment to integrating diagnostics with therapeutic interventions.​

Federal agencies, notably the National Institutes of Health (NIH), are actively funding biomarker research to enhance clinical trials and therapeutic development. The NIH's Notice of Funding Opportunity (NOFO), PAR-25-024, promotes the development of candidate biomarkers to improve clinical trial efficiency and patient care decisions. Such initiatives underscore the federal dedication to advancing biomarker-based diagnostics.​

The FDA's pilot program for oncology drug products used with specific in vitro diagnostic tests exemplifies regulatory efforts to streamline the approval process for companion diagnostics. This program facilitates the concurrent development of drugs and their companion diagnostics, expediting patient access to personalized therapies.​

In neurology, the National Institute of Neurological Disorders and Stroke (NINDS) supports biomarker research to enhance neurotherapeutic clinical trials. Such funding fosters the development of biomarkers for neurological diseases, aiding in early diagnosis and personalized treatment approaches.​

These developments highlight a dynamic shift towards personalized medicine in the U.S., with regulatory bodies and research institutions actively promoting biomarker and companion diagnostic advancements. This trend drives demand for specialized bioanalytical testing services, propelling market growth and innovation.

Integration of Automation and Digital Technologies in Laboratories

​The integration of automation and digital technologies in laboratories is significantly transforming the United States Bioanalytical Testing Services Market. As laboratories face increasing pressure to enhance accuracy, improve efficiency, and reduce operational costs, automation is emerging as a crucial solution. Automated systems for sample handling, assay processing, and data analysis streamline bioanalytical workflows, reducing human errors and ensuring consistent results across large-scale testing environments. Laboratories are increasingly adopting platforms like Laboratory Information Management Systems (LIMS) that enable efficient data management, traceability, and compliance with regulatory requirements.

The adoption of digital technologies, including cloud-based data storage and AI-powered analytics, is also improving the accessibility and analysis of complex data sets. By leveraging cloud solutions, laboratories can securely store vast amounts of bioanalytical data and ensure real-time access for scientists, researchers, and stakeholders. This cloud-based model supports collaborative efforts and enhances data-sharing capabilities, further speeding up the research and development process. AI and machine learning algorithms play a pivotal role in automating data analysis, offering more accurate insights by identifying patterns, correlations, and anomalies that might otherwise go unnoticed. This technology also supports predictive modeling, which helps in making more informed decisions in the drug development process.

The integration of these technologies is particularly valuable in high-throughput environments, where rapid scaling is essential to meet the demands of clinical trials and regulatory timelines. By improving operational efficiency and data accuracy, automated and digital systems are helping laboratories handle increasing sample volumes and complex bioanalytical tests. This trend is expected to continue driving growth in the bioanalytical testing services market as labs embrace these innovations to stay competitive and meet evolving industry demands.

Segmental Insights

Molecule Insights

Based on the Molecule, Small Molecule emerged as the dominant segment in the United States Bioanalytical Testing Services Market in 2024. This is due to their widespread use in pharmaceutical drug development. Small molecules are typically used in the formulation of most drugs, and their testing is critical for ensuring safety, efficacy, and compliance with regulatory standards. The pharmaceutical industry is heavily focused on small molecule-based therapies, which are commonly used for a variety of conditions, including cancer, cardiovascular diseases, and neurological disorders. These drugs often undergo rigorous bioanalytical testing to determine their pharmacokinetics, pharmacodynamics, and overall therapeutic profiles. The dominance of small molecules in bioanalytical testing services can also be attributed to their relatively simpler chemical structures compared to biologics, making them easier to analyze using traditional bioanalytical techniques like liquid chromatography-mass spectrometry (LC-MS) and high-performance liquid chromatography (HPLC). This has led to the widespread availability of standardized testing methods, driving the segment’s growth.

Test Insights

Based on the Test, Bioavailability emerged as the dominant segment in the United States Bioanalytical Testing Services Market in 2024. This is due to its critical role in drug development and regulatory approval processes. Bioavailability refers to the proportion of a drug that enters the bloodstream when administered and is made available for therapeutic action. Ensuring the bioavailability of a drug is essential for determining its efficacy and safety, making it a vital part of clinical trials, particularly for new drug formulations and dosage forms. This testing is integral to assessing how quickly and to what extent a drug is absorbed, distributed, metabolized, and eliminated from the body. With the rise in complex drug formulations and the increased focus on personalized medicine, bioavailability testing has become increasingly important. Regulatory bodies such as the FDA require bioavailability studies for drug approval, contributing to the high demand for these services.

Download Free Sample Report

Regional Insights

The Mid-West region emerged as the dominant region in the United States Bioanalytical Testing Services Market in 2024. This is due to several factors, primarily its strategic position as a hub for pharmaceutical and biotechnology companies. This region is home to numerous research institutions, contract research organizations (CROs), and large pharmaceutical firms, all of which are crucial players in the bioanalytical testing services sector. With a strong presence of clinical research infrastructure, the Mid-West offers an ideal environment for the growth of the bioanalytical testing services market. Moreover, the region benefits from cost-effective operations compared to coastal areas, making it attractive for companies to set up their R&D and testing facilities. The Mid-West's well-established regulatory environment, skilled workforce, and proximity to major medical centers further enhance its position in the bioanalytical testing services market. The strong focus on drug development, particularly in the fields of oncology, neurology, and infectious diseases, has contributed to the increasing demand for bioanalytical testing services in this region.

Recent Developments

• In March 2025, NAMSA announced the acquisition of WuXi AppTec's U.S. medical device testing operations, marking a significant step towards expanding its leadership in biological safety testing for medical devices. This strategic acquisition combines the strengths of both companies, offering a comprehensive suite of testing solutions to more than 4,000 medical device manufacturers globally. The merger will enhance NAMSA's capabilities in supporting the development, safety, and regulatory compliance of medical devices, providing critical testing services for a diverse client base.
• In August 2024, SGS launched its specialized bioanalytical testing services in Hudson, New Hampshire, expanding its service offerings in North America. This new facility is designed to provide state-of-the-art bioanalytical testing for both biopharmaceutical and pharmaceutical companies, addressing the increasing demand for advanced testing services. SGS’s new bioanalytical services will help drug developers streamline the development process by offering high-quality analytical capabilities, ensuring the safety and efficacy of pharmaceutical products.
• In April 2024, Eurofins Scientific, a global leader in bioanalytical testing, completed its acquisition of Ascend Clinical, LLC, the largest independent kidney dialysis testing laboratory in the U.S. Ascend offers automated chemistry, hematology, microbiology, and virology testing services to dialysis clinics and hospitals nationwide. The company also provides water and dialysate testing, enhancing patient safety and supporting successful regulatory audits. The acquisition strengthens Eurofins' position in transplant testing and renal care, expanding its client base. In return, Ascend gains access to Eurofins' extensive laboratory network and resources.
• In March 2024, Pace Analytical Services completed the acquisition of a laboratory facility in Lebanon, New Jersey, from Curia. This acquisition enhances Pace Analytical's ability to support emerging drug development partners by offering rapid, expert development and commercial analytical laboratory services. The move is expected to strengthen Pace Analytical’s position in the biopharma sector, providing crucial support for companies in the drug development pipeline.
• In March 2024, EPNextS Group, a leading Japanese provider of clinical trial solutions, partnered with Frontage Laboratories, Inc., a US-based contract research organization (CRO), to tackle the issues of "Drug Lag" and "Drug Loss" in Japan. These challenges hinder the timely introduction of new drugs and patient access to critical medications due to delays in regulatory processes and clinical trials. The collaboration aims to combine EPNextS Group's clinical trial expertise with Frontage's experience in early-phase drug development to improve the efficiency of the drug development process, accelerating access to life-saving therapies in Japan.

Key Market Players

• Thermo Fisher Scientific, Inc.
• ICON plc
• Charles River Laboratories International, Inc.
• Laboratory Corporation of America Holdings
• IQVIA Inc.
• Syneos Health
• SGS SA
• Intertek Group Plc
• Pace Analytical Services, LLC
• Medpace Holdings, Inc.

Report Scope:

In this report, the United States Bioanalytical Testing Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Bioanalytical Testing Services Market, By Molecule:

o   Small Molecule

o   Large Molecule

• United States Bioanalytical Testing Services Market, By Test:

o   ADME

o   Pharmacokinetics (PK)

o   Pharmacodynamics (PD)

o   Bioavailability

o   Bioequivalence

o   Biomarker Testing

o   Cell-based Assay

o   Virology Testing

o   Others

• United States Bioanalytical Testing Services Market, By Workflow:

o   Sample Collection and Preparation

o   Method Development and Validation

o   Sample Analysis

o   Other Processes

• United States Bioanalytical Testing Services Market, By End User:

o   Pharma & BioPharma Companies

o   CDMO

o   CRO

o   Others

• United States Bioanalytical Testing Services Market, By Region:

o   North-East

o   Mid-West

o   West

o   South

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United States Bioanalytical Testing Services Market.

Available Customizations:

United States Bioanalytical Testing Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

United States Bioanalytical Testing Services Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com